BRIEF—Boehringer COPD and asthma inhalers now available for $35 a month

German family-owned pharma major Boehringer Ingelheim’s new program to cap out-of-pocket costs at $35 per month for eligible patients for the company’s inhalers is now available.

With this program, patients who have had difficulty navigating the current healthcare system will now be able to afford the Boehringer inhalers they need.

“Ensuring equitable access to life-saving medications is not just a commitment—it’s our responsibility,” said Jean-Michel Boers, president and chief executive of Boehringer Ingelheim USA Corporation.

“This program and its $35 cost to patients applies to our entire portfolio of inhalers, making them affordable to all eligible patients, including the most vulnerable patients, such as those who are uninsured or underinsured. While we recognize this is just one solution, we see it as a stepping-stone in our ongoing commitment to ensure the healthcare system is fairer and simpler for all patients.”

The program applies to all Boehringer Ingelheim inhalers, including: